The Tech Council of Maryland, Maryland's largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, today announced that Art Jacoby is stepping down from his CEO duties effective February 15, 2013 to return full-time to his consulting practice. TCM has commenced an executive search to identify its next CEO.

"I want to thank Art for his exemplary leadership of TCM," said Larry Letow, chairman of the Tech Council, who also is president and CEO of Convergence Consulting. "We have accomplished a great deal during his tenure and wish him success in his consulting practice. Moving forward, the TCM Board will conduct a thorough executive search that takes into consideration the valuable insights of TCM stakeholders. We look forward to identifying the best possible leader to advance TCM's mission of helping Maryland technology companies collaborate, grow and succeed."

As healthcare providers implement the changeover to electronic medical records and meaningful use requirements, the opportunities seen by health IT companies aren’t restricted to US businesses. The Consulate General of Canada in Philadelphia is planning to launch a health IT accelerator at the beginning of next year. The goal? To help Canadian companies to chase a significantly larger market with the potential to grow US jobs in the process.

Vincent Finn, a Philadelphia-based trade commissioner with the Consulate General of Canada, said the initiative has the potential to create high-paid jobs. Canada has already established technology accelerators in San Francisco and New York and a clean energy accelerator in New York. The companies selected for the health IT accelerator at the University City Science Center will be among those Canadian companies participating in the upcoming eHealth summit scheduled for November 28.

The latest joint venture between the University of Maryland, College Park and University of Maryland, Baltimore will combine computer know-how from College Park and Baltimore’s wealth of medical researchers.

The Center for Health-related Informatics and Bioimaging will focus on projects that use technological advancements to improve medicine and patient care. The overarching goal will be to advance the idea of personalized medicine, through which doctors use advance technology and biomedical information to tailor treatment decisions to individual patients.

When Gail Folena-Wasserman joined Gaithersburg biotechnology startup MedImmune in 1991, she was its first employee in research and development, and dreamed of what the company might be "when it grew up."

Two decades later, the senior vice president for biopharmaceutical development is helping to test new drugs at a dramatically different MedImmune. Five years since a $15 billion acquisition by British pharmaceutical giant AstraZeneca, the company is funneling a pipeline of potential therapies that has grown three times over and covers a wider spectrum of diseases.

 Startup Maryland is proud to announce that CoFounders Lab (Rockville, Md.) has claimed the top spot in its Pitch Across Maryland competition. The company was named the winner in the video pitch competition at the Maryland Entrepreneur Expo on November 13, by a panel of distinguished judges. The judges also named Woofound (Baltimore, Md.) as the runner-up.

As the winner and runner-up, CoFounders Lab and Woofound will receive free entry and bypass the first round of judging in the InvestMaryland Challenge, a national seed and early-stage business competition hosted by the State of Maryland. All Pitch Across Maryland participants are encouraged to apply.

There is a host of websites for people who want to link up for personal relationships.

CoFoundersLab of Rockville wants to do something similar, but for business relationships — specifically launching a new venture.

The company has attracted notice from many local entrepreneurs. Judges who viewed the video that CoFoundersLab submitted to the Startup Maryland pitch contest in September liked the concept enough to name it the winner of the “Pitch Across Maryland” contest this week over almost 200 competitors.

Arizona's first-of-its-kind statewide technology transfer startup program, AZ Furnace Accelerator, is pleased to announce it has selected the first 10 startups that will participate in the business accelerator program. As part of the competitive process, a panel of judges selected the 10 winners from a group of 22 finalists and more than 50 applicants.

The AZ Furnace Accelerator is a groundbreaking initiative that encourages entrepreneurs from across the country to find and commercialize innovations developed within the state's universities and research institutions. These 10 winning companies utilized innovations from Arizona State University, Dignity Health Arizona, Northern Arizona University and University of Arizona. They represent a wide array of technologies and innovative solutions — from biomarkers for disease diagnosis to new methods for massive data storage to repurposing discarded tires for new concrete and construction materials:

The first question most people seem to ask when contemplating a new startup is where they will get investor money. That’s certainly a valid question, but all the money in the world won’t make your business a success if you hate what you are doing, and you don’t have a plan to use it. I suggest that there are several other questions even more important than the money one.

The best way to assure the success of your startup is to do something you love, as opposed to something that will make you a lot of money. Of course, all these things and many more are critical, so it’s important that you keep your priorities straight. Here are the right questions to ask yourself, in the right order, before asking others about money:

Brenda McKenzie, a high-ranking economic development official in Boston, is expected to be named on Monday as the next president of the Baltimore Development Corp., according to multiple sources.

McKenzie joined the Boston Redevelopment Authority in 2008 and is currently the agency's director of economic development. Prior to her time in Boston, she managed government and external affairs in Starbucks Coffee Co.’s corporate social responsibility division. McKenzie also spent 11 years working in city government in Chicago, rising to the role of deputy commissioner of the Chicago Planning and Development Department.

Startup Maryland, today announced the 8 Finalist for the Pitch Across Maryland competition.  After posting the 168 video pitches from Maryland entrepreneurs that were captured during the three-week Pitch Across Maryland bus tour, Startup Maryland is proud to reveal the Eight (8) Finalists that were selected by a panel of entrepreneur and investor experts.

The following link takes you to a Playlist with the 8 Finalists:

http://www.youtube.com/playlist?list=PLBN03TRv8YYfeHdh_p9eiKVx-VG5qIK3o

What happens when the FDA approval process slows down and imposes higher hurdles, when cost-reduction becomes central to the healthcare provider business model, when clinical trials and commercialization costs for medical devices and biotechnology products spiral through the roof, and when exit returns are compressed by general economic conditions and the decline of the IPO market?

Venture capital funding for early stage life science companies markedly contracts. In fact, venture capital funding for these companies declined consistently over the last few years. Even if federal grant funding for basic research increases, there will still remain the proverbial “valley of death” in funding the necessary first steps of translating research into products and ideas into companies. The emerging life sciences company must find a bridge to the development and commercialization of new life-saving technologies.

Commemorating a year that positioned Maryland as a national leader in the innovation economy, DBED has released its FY 2012 Annual Report. Highlights include the continued progress of InvestMaryland, the passage of the Maryland Innovation Initiative, successful trade missions to India and Asia, and the development of interactive tools for businesses including a mobile-friendly website, an online site selection database, an interactive map and Finance Tracker. DBED helped create or retain more than 7,335 jobs and leveraged $661 million in capital investment through 111 projects. In addition, Maryland visitors spent $13.1 billion on travel expenses and the Maryland State Arts Council awarded more than $11 million in grants.

Maryland is the nation’s second best educated state with 36.9 percent of its population aged 25 or over holding a bachelor’s degree or higher, 24/7 Wall St. reported, citing data from the U.S. Census Bureau’s’ American Community Survey.

Additionally, 16.5 percent of the population holds a graduate or professional degree of some kind, ranking only behind Massachusetts, the business news site said.

As part of today’s Maryland Entrepreneur Expo 2012 hosted by TEDCO, Maryland Department of Business and Economic Development (DBED) Secretary Christian S. Johansson announced that the State has invested $1.1 million in three start-up companies through the InvestMaryland program. Rockville-based Maxtena will receive a $560,000 investment, and two Baltimore companies – Bambeco and PathSensors – will receive investments of $400,000 and $200,000, respectively. The investments are among the first made through the State’s $84 million venture capital program. The first investment was $250,000 to Bethesda-based Brainscope in September.

“When we make strategic investments in cutting-edge companies like Maxtena, PathSensors and Bambeco, we are strengthening Maryland’s leadership in the Innovation Economy,” said Governor Martin O’Malley. “With a total of $84 million to invest in the State’s best and brightest start-ups, we are stimulating our economy and creating jobs not just for today, but for generations to come.”

On November 8, 2012, the BioPark hosted Rachel King, CEO of GlycoMimetics, as part of its Business of Bio speaker series. Ms. King spoke before an active, question-filled audience from the University of Maryland campus in Baltimore and from bioscience companies throughout the region.

Opening her discussion with a review of the venture financing climate within the life sciences industry during 2012, Ms. King said, “There is a challenge today with respect to the risk level that a venture capitalist is willing to take. Investments are going towards later-stage programs. That’s not to say early deals don’t get done – but they are harder to secure.”

Not that long ago, biotech executives weren’t sure who to call on Wall Street, or whether anyone would answer the phone. In late 2008 and early 2009, nobody could say for sure who would still be around in a couple years to supply capital to aspiring drugmakers.

Partly inspired by all the recent election-year reflection, I decided to look back at what biotech executives were saying about the financial crisis during some of the darker moments in January 2009. It was a scary time for the industry. Check this comment from an interview with Richard Pops, the CEO of Alkermes (NASDAQ: ALKS) at the JP Morgan Healthcare Conference that year:

GlaxoSmithKline, the new owner of Rockville's Human Genome Sciences, cleared a significant regulatory hurdle last week when a Food and Drug Administration advisory panel overwhelmingly recommended that its anthrax treatment be approved.

Under a federal contract, HGS began work on raxibacumab, which it brands ABthrax, shortly after the anthrax attacks in September 2001 that infected 11 people, killing five of them.

MedImmune, the global biologics arm of AstraZeneca PLC operating through various affiliates in the AstraZeneca Group, has approximately 5,500 full-time employees and contractors worldwide and is headquartered in Gaithersburg, Maryland. MedImmune is a $1 billion corporation with plans and aspirations to be a $10 billion corporation by 2020. TEKsystems has been a MedImmune partner since 2001.

Project Overview Following its acquisition by AstraZeneca, MedImmune decided to reallocate, and in some cases eliminate, a variety of roles in its IT department in favor of outsourcing a few key IT support functions to an alternative vendor. This change left MedImmune with a very small technical staff mostly comprised of service delivery managers tasked with managing the outputs from the vendor.

Gaithersburg-based MedImmune is the global biologics arm of AstraZeneca PLC, with approximately 3,500 employees worldwide.

MedImmune’s Synagis® product is the first monoclonal antibody approved for the prevention of an infectious disease, as well as the first such drug to be safely used in children.

Synagis® prevents a serious lower respiratory tract disease caused by the respiratory synctial virus (RSV), prominent in the Northern Hemisphere during the winter months. RSV is the most common respiratory infection for infants and children. Approximately 50 percent of all infants are infected with RSV during their first year of life; nearly all children have been infected at least once by the time they reach their second birthday.

QIAGEN N.V. has announced the first product launches in its initiative to advance routine workflows in next-generation sequencing (NGS) applications. At the annual meeting of the American Society of Human Genetics (ASHG) in San Francisco, QIAGEN will present four new products that improve critical sample preparation processes in the pre-analytical phase of next-generation sequencing. At ASHG, QIAGEN also will provide an outlook on additional pre-analytical products under development for advanced NGS workflow solutions, which are planned for launch in early 2013.

The QIAGEN pre-analytical products are “universal,” compatible with any NGS platform in the market and functional in a wide range of NGS applications. They represent the first launches in the QIAGEN initiative unveiled earlier this year, which aims to integrate sample preparation products and novel assay technologies into complete workflows for next-generation sequencing.

Medical innovation is the key to addressing the big unmet needs in neurodegeneration, metabolic and heart disease, cancer, among many other conditions.  Not only do new therapeutics and devices aimed at this diseases offer clinical promise, but they also can provide significant health economics benefits.

This combination – clinically meaningful advance coupled with sound economics – is what those of us in the life science R&D funding ecosystem focus on every day.  On the venture side, figuring out how to generate returns from medical advances requires us to innovate both with regards to products and business models.

SAIC has won several contracts this quarter totaling approximately $242 million from the government and commercial healthcare industry, the company announced today.

“This has been an important quarter for our health solutions team, as we work to unify our commercial healthcare teams and leverage their skills across both the commercial and federal markets,” said Steve Comber, SAIC senior vice president and health solutions business unit general manager.

Applications Deadline EXTENDED: November 14, 2012 Program Selection: November 21, 2012

What is CAP?

The NIH Commercialization Assistance Program (CAP) is a specialized technical assistance program for SBIR/STTR Phase II awardees. CAP is designed to help promising small life science companies develop their commercial businesses and transition their SBIR/STTR - developed technologies into the marketplace.

Assisting small businesses is a top priority for the NIH in ensuring the success of the SBIR/STTR programs and maximizing the agency's investment. Since the program's inception in 2003, NIH has provided approximately 700 participants with individualized assistance toward accomplishing their commercialization goals. This is achieved through training workshops, individual mentoring and consulting sessions, as well as public events in which companies present their technologies to the investment community, potential strategic partners and licensees.

National Institutes of Health (NIH) Director Francis Collins debuted his new NIH Director's Blog last week. The blog, he wrote, is designed to "highlight new discoveries in biology and medicine that I think are game changers, noteworthy, or just plain cool." Posts so far have featured video from a recent "Celebration of Science" event held at NIH and information about the Human Connectome Project, an NIH-funded project created to map the brain's neural connections.

A new guide funded by the Agency for Healthcare Research and Quality (AHRQ) “Designing Consumer Health IT: A Guide for Developers and Systems Designers” presents suggested recommendations for designers and developers of consumer health IT products. Recommendations included are either general guidance for designers and design teams that can be applied to the process of designing and developing a product; or specific to a design phase such as idea generation, identification of end users, testing and commercialization. The guide presents results of an environmental scan and grey literature review; and expert interviews to improve consumer health IT design in order to increase effective use of consumer health IT. Select to access this report (PDF file, 299 MB), http://healthit.ahrq.gov/developmentmethodsguide.

Learning CPR was the best part of Anne Selby’s day on Oct. 26. For her classmate Daniel Aguilar, it was learning how to operate robotic limbs.

Anne said when she grows up, she wants to be a nurse or a teacher. Daniel said he wants to be a mechanic.

The seventh-graders at Forest Oak Middle School viewed Frontiers in Science and Medicine Day, which took place at the Universities at Shady Grove in Rockville, as an exciting learning experience outside the classroom.

Undocumented immigrants will begin paying in-state tuition rates at Maryland public colleges and universities in the wake of voters’ overwhelming support of the policy Tuesday at the ballot box.

Thirteen other states have adopted measures similar to the Maryland Dream Act, but it is the first of its kind to have survived a statewide popular vote.

Ambit Biosciences Inc. has closed a $25 million of a new $50 million financing, the company announced. Existing investor OrbiMed Advisors led the financing with participation from other existing investors including Aisling Capital, Apposite Healthcare,Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV, and Radius Ventures. Ambit is a biopharmaceutical company developing “small molecule kinase inhibitors” for the treatment of cancer, inflammatory disease and other conditions.

“2012 has been a pivotal year of progress for Ambit, and this financing is a reflection of that progress and the momentum we have built as a team,” said Michael Martino, President and CEO of Ambit. “We’ve received the data from our large, 333 patient Phase 2 trial of quizartinib in patients with relapsed/refractory AML, and we are excited to present that data at ASH in Atlanta in December. We’ve refocused and prioritized our work on earlier stage pipeline assets, including our oral JAK2 and CSF1R inhibitor programs, and re-energized the team. This financing, with OrbiMed Advisors leading a round in which all existing investors participated, is a strong vote of confidence in our direction and provides the resources to accelerate our progress in 2013.”"

Being one of the top institutions for higher education in the nation is something the UMBC community prides itself on. To continue along the ambitious path UMBC has already made, President Freeman A. Hrabowski III has created the Fund for Innovation Competition.

"I anticipate the advancements proposed will reflect the long standing dedication and commitment of our faculty to support the success of students" said Philip Rous, Provost and Senior Vice President of Academic Affairs. Rous, along with other UMBC administration officials, has worked hard organizing and developing the framework for the competition.

Johns Hopkins researchers have succeeded in teaching computers how to identify commonalities in DNA sequences known to regulate gene activity, and to then use those commonalities to predict other regulatory regions throughout the genome. The tool is expected to help scientists better understand disease risk and cell development.

The work was reported in two recent papers in Genome Research, published online on July 3 and Sept. 27.

“Our goal is to understand how regulatory information is encrypted and to learn which sequence variations contribute to medical risks,” says Andrew McCallion, Ph.D., associate professor of molecular and comparative pathobiology in the McKusick-Nathans Institute of Genetic Medicine at Hopkins. “We give data to a computer and ‘teach it’ to distinguish between data that has no biological value versus data that has this or that biological value. It then establishes a set of rules, which allows it to look at new sets of data and apply what it learned. We’re basically sending our computers to school.”

Running a company that processes credit card information can help an executive keep his finger on the pulse of the economy.

Hossein Noshirvani has enjoyed this perspective for eight years while managing Motionsoft, a Rockville company that provides membership management services for health clubs.

“There’s been a nice upward trend in both the economy and memberships within the last year,” said Noshirvani, whose company’s sales have improved to the point that it requires more employees.

Despite the huge amounts of money that the pharmaceutical industry spends on drug discovery, it is notoriously old-fashioned in how it actually makes its products. Most drugs are made in batch processes, in which the ingredients, often powders, are added in successive and often disconnected steps. The process resembles a bakery more than it does a modern chemistry lab. That could be about to change.

This summer, a team of researchers from MIT and Swiss pharmaceutical company Novartis proved that a continuous production line that integrated several new chemical processes and equipment specially designed for the project could make a higher quality drug faster, and in a less wasteful manner.  This more nimble method may even create more opportunities in early drug discovery. In their continuous-manufacturing process, raw ingredients are fed into a parade of heaters, spinners, extractors, and sensors that relay the intermediates through chemical reactions. At the end, round, coated pills fall out.

Salaries hinted at a recovery last year after a noticeable dip in 2010—the first-ever drop in The Scientist’s 10-year history of surveying the life science community. But this year, salaries remained relatively flat overall compared with 2011, and even regressed in some areas. In contrast to the steady growth observed in The Scientist’s Salary Survey since 2001, the past few years stand out as a distinct plateau, with 2012 median total earnings (salaries plus fees, bonuses, and profit sharing) of $87,000 falling just below the $90,000 our readers reported in 2009. However, the overall flatness in the 2012 median earnings disguises big changes across sectors and regions of the country.

This year’s high-scoring disciplines included bioengineering, biophysics, and food/nutrition science. Earnings in traditional research specialties, on the other hand, took a significant hit: median total compensation for researchers in endocrinology dropped by more than $30,000 from 2011, systems biologists’ take-home pay dipped by $38,500, and those in cancer/oncology took home some $15,000 less than median earnings last year.

McLean-based SAIC Inc., which said in August it would split its operations into two separate, publicly traded companies, says current chief executive John Jumper will continue to head the national security and health and engineering business, the larger of the two new companies.

SAIC insider Tony Moraco, who currently heads SAIC’s intelligence, surveillance and reconnaissance business, will be chief executive of the newly formed government technical services and enterprise IT business.

The Maryland Stem Cell Research Commission (Commission) announced today that it has received the 2012 Excellence in Technology-Based Economic Development (TBED) Award from the State Science and Technology Institute (SSTI). This award, presented at SSTI's 16th annual conference in Atlanta, recognizes the Maryland Stem Cell Research Fund (MSCRF) programs for providing competitive grants to public and private entities, advancing cutting-edge research and technology, leveraging state funds, and developing strong economic growth in the life sciences sector. The Excellence in TBED Award follows a national competition to identify the most effective and innovative approaches to building tech-based state and regional economies. The MSCRF is one of only six agencies nationwide to have received this prestigious award.

The MSCRF, which is administered by the Maryland Technology Development Corporation (TEDCO), received this award in the "Expanding the Research Capacity" category for its best practice models in technology-based economic development. MSCRF funding supports a variety of grant programs for stem cell research in Maryland, with the dual goal of developing new medical strategies for the prevention, diagnosis and treatment of human diseases and spurring economic development in the State.